Concurrent Session 09: News in Therapies

Moderators: Jean Liew & Nancy Lane

Rediscovering Botulinum Toxin in OA
Christelle Nguyen

• Botulinum toxin A is a neurotoxin produced by Clostridium botulinum that inhibits acetylcholine release into the synaptic cleft in cholinergic nerve terminals. 
• Botulinum toxin A has also shown intrinsic antinociceptive effects in various models of joint diseases and its intra-articular use in OA has raised recent interest.
• Herein, we will critically review putative mechanisms of action Botulinum toxin A and evidence arising from basic and clinical research for its interest in OA.

Abstract Presentations:

63 EFFICACY OUTCOMES IN PATIENTS WITH KNEE OSTEOARTHRITIS: PER-PROTOCOL ANALYSES FROM SPRINGBOARD, A PHASE 2, RANDOMIZED, 24-WEEK STUDY OF EP-104IAR (LONG-ACTING INTRA-ARTICULAR INJECTION OF FLUTICASONE PROPIONATE)        
James A. Helliwell

64 DICKENS: A MULTICENTRE RANDOMIZED CONTROLLED TRIAL OF DIACEREIN FOR KNEE OSTEOARTHRITIS WITH EFFUSION-SYNOVITIS      
Dawn Aitken

65 EFFICACY AND SAFETY OF AN INTRA-ARTICULAR PLACENTAL TISSUE PARTICULATE (MOTYS/PTP-001) IN SYMPTOMATIC KNEE OSTEOARTHRITIS OVER 26 WEEKS: A PLACEBO-CONTROLLED, DOUBLE-BLIND RANDOMIZED CLINICAL TRIAL          
Alessandra Pavesio

66 EFFECTS OF PENTOSAN POLYSULFATE SODIUM ON CLINICAL OUTCOMES AND DISEASE MODIFYING BIOMARKERS IN MODERATE TO SEVERE KNEE OSTEOARTHRITIS          
Mukesh Ahuja

67 A RANDOMIZED PLACEBO-CONTROLLED TRIAL OF ORAL RESVERATROL FOR PATIENTS WITH PAINFUL KNEE OSTEOARTHRITIS (ARTHROL)             
Christelle Nguyen